Literature DB >> 1879094

Uses and limitations of nuclear magnetic resonance (NMR) spectroscopy in clinical pharmacokinetics.

M C Malet-Martino1, R Martino.   

Abstract

Mesh：

Year:  1991        PMID： 1879094     DOI： 10.2165/00003088-199120050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  29 in total

1.  A rapid method for the isolation and identification of drug metabolites from human urine using solid phase extraction and proton NMR spectroscopy.

Authors:  I D Wilson; I M Ismail
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

2.  Solid phase extraction chromatography and NMR spectroscopy (SPEC-NMR) for the rapid identification of drug metabolites in urine.

Authors:  I D Wilson; J K Nicholson
Journal:  J Pharm Biomed Anal       Date:  1988       Impact factor: 3.935

Review 3.  High resolution nuclear magnetic resonance spectroscopy of biological samples as an aid to drug development.

Authors:  J K Nicholson; I D Wilson
Journal:  Prog Drug Res       Date:  1987

4.  Release of fluoride ion from 5'-deoxy-5-fluorouridine, an antineoplastic fluoropyrimidine, in humans.

Authors:  R Martino; A Lopez; M C Malet-Martino; J Bernadou; J P Armand
Journal:  Drug Metab Dispos       Date:  1985 Jan-Feb       Impact factor: 3.922

5.  Application of fluorine-19 nuclear magnetic resonance to the determination of plasma-protein binding of 5'-deoxy-5-fluorouridine, a new antineoplastic fluoropyrimidine.

Authors:  D Meynial; A Lopez; M C Malet-Martino; J S Hoffmann; R Martino
Journal:  J Pharm Biomed Anal       Date:  1988       Impact factor: 3.935

Review 6.  In vivo 19F nuclear magnetic resonance spectroscopy: a potential monitor of 5-fluorouracil pharmacokinetics and metabolism.

Authors:  J L Evelhoch
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

7.  Direct detection of new flucytosine metabolites in human biofluids by 19F nuclear magnetic resonance.

Authors:  J P Vialaneix; M C Malet-Martino; J S Hoffmann; J Pris; R Martino
Journal:  Drug Metab Dispos       Date:  1987 Sep-Oct       Impact factor: 3.922

8.  19F NMR spectrometry evidence for bile acid conjugates of alpha-fluoro-beta-alanine as the main biliary metabolites of antineoplastic fluoropyrimidines in humans.

Authors:  M C Malet-Martino; J Bernadou; R Martino; J P Armand
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

9.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.

Authors:  W E Hull; R E Port; R Herrmann; B Britsch; W Kunz
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

10.  Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo.

Authors:  P M McSheehy; M J Prior; J R Griffiths
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640
View more
  2 in total

Review 1.  Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.

Authors:  P Chrisp; D McTavish
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

2.  Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.

Authors:  L Lemaire; M C Malet-Martino; M de Forni; R Martino; B Lasserre
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.